| scholarly article | Q13442814 |
| P50 | author | Raphael Mechoulam | Q903973 |
| P2093 | author name string | Yossi Gilgun-Sherki | |
| Eldad Melamed | |||
| Daniel Offen | |||
| P2860 | cites work | Nonpsychotropic cannabinoid acts as a functional N-methyl-D-aspartate receptor blocker | Q24601670 |
| Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants | Q24685540 | ||
| Enhanced oxidative stress and altered antioxidants in brains of Bcl-2-deficient mice | Q28593905 | ||
| From gan-zi-gun-nu to anandamide and 2-arachidonoylglycerol: the ongoing story of cannabis | Q33636913 | ||
| Enantiomeric cannabinoids: stereospecificity of psychotropic activity | Q34178353 | ||
| Brain cannabinoid systems as targets for the therapy of neurological disorders | Q34492167 | ||
| Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. | Q34602111 | ||
| A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment | Q37585084 | ||
| Nonaminergic striatal neurons convert exogenous l-dopa to dopamine in parkinsonism | Q40123863 | ||
| Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease | Q42541635 | ||
| Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease | Q42542290 | ||
| Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study | Q43820144 | ||
| Acute effects of pulsatile levodopa administration on central dopamine pharmacodynamics | Q44009726 | ||
| A 6-hydroxydopamine-induced selective parkinsonian rat model | Q46617652 | ||
| Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action | Q48309971 | ||
| Cannabinoid effects in basal ganglia in a rat model of Parkinson's disease | Q48435185 | ||
| Role of the subthalamic nucleus in cannabinoid actions in the substantia nigra of the rat. | Q48786464 | ||
| Effects of intranigral cannabinoids on rotational behavior in rats: interactions with the dopaminergic system | Q49060851 | ||
| Anandamide: a candidate neurotransmitter heads for the big leagues. | Q51090766 | ||
| Cannabinol and cannabidiol in combination: temperature, open-field activity, and vocalization | Q68006646 | ||
| The cannabinoid agonists WIN 55,212-2 and CP 55,940 attenuate rotational behavior induced by a dopamine D1 but not a D2 agonist in rats with unilateral lesions of the nigrostriatal pathway | Q70973782 | ||
| Neuroprotective and antioxidant activities of HU-211, a novel NMDA receptor antagonist | Q71583483 | ||
| Characterization of the hypothermic effect of the synthetic cannabinoid HU-210 in the rat. Relation to the adrenergic system and endogenous pyrogens | Q71898948 | ||
| Dopaminergic regulation of cannabinoid receptor mRNA levels in the rat caudate-putamen: an in situ hybridization study | Q72656516 | ||
| Correlation of apomorphine- and amphetamine-induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats | Q72707580 | ||
| Synthesis of a primary metabolite of cannabidiol | Q73071391 | ||
| P433 | issue | 2 | |
| P921 | main subject | levodopa | Q300989 |
| cannabinoid receptor | Q421237 | ||
| cannabinoids | Q422936 | ||
| CNR2 | Q17907844 | ||
| P304 | page(s) | 66-70 | |
| P577 | publication date | 2003-08-01 | |
| P1433 | published in | Basic and Clinical Pharmacology and Toxicology | Q15724438 |
| P1476 | title | The CB1 cannabinoid receptor agonist, HU-210, reduces levodopa-induced rotations in 6-hydroxydopamine-lesioned rats | |
| P478 | volume | 93 |
| Q48444953 | Alterations in behavioral flexibility by cannabinoid CB1 receptor agonists and antagonists |
| Q36155898 | Cannabinoids and Dementia: A Review of Clinical and Preclinical Data |
| Q42095959 | Detection of cannabinoid receptors CB1 and CB2 within basal ganglia output neurons in macaques: changes following experimental parkinsonism |
| Q24814542 | Harm reduction--the cannabis paradox |
| Q37512670 | Marijuana Compounds: A Nonconventional Approach to Parkinson's Disease Therapy. |
| Q37924629 | Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation. |
| Q41809772 | Nigrostriatal denervation changes the effect of cannabinoids on subthalamic neuronal activity in rats. |
| Q36364388 | Shedding light into the role of BDNF in the pharmacotherapy of Parkinson's disease. |
| Q99615888 | The effect of intra-striatal administration of GPR55 agonist (LPI) and antagonist (ML193) on sensorimotor and motor functions in a Parkinson's disease rat model |
| Q24648473 | The endocannabinoid system as an emerging target of pharmacotherapy |
| Q35171113 | The therapeutic potential of cannabinoids for movement disorders |
Search more.